L&C BIO

엘앤씨바이오 · 290650

Health Care Pharmaceuticals · KOSDAQ

Large-cap

Market cap US$1.5B (₩2.1T)

Overview

L&C BIO makes human tissue-derived products, biological materials processed from donated human tissue and used in surgical procedures such as bone grafts and wound repair.

Its products are supplied to hospitals and surgical teams. The company is listed on KOSDAQ, South Korea's tech and small-cap exchange. The filing text does not clearly specify a single dominant product line or structural business model beyond its tissue-based medical product portfolio.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025

Revenue · FY2025

US$61.9M

▲ +18.6% YoY

Operating profit · FY2025

US$3.2M

▲ +73.7% YoY

Net income · FY2025

−US$100.2M

Turned to loss

Revenue, operating profit and net income by fiscal year (USD; KRW in parentheses).
Metric	FY2023	FY2024	FY2025
Revenue	US$49.9M(₩68.9B)	US$52.2M(₩72.1B)	US$61.9M(₩85.5B)
Operating profit	US$5.6M(₩7.7B)	US$1.8M(₩2.5B)	US$3.2M(₩4.4B)
Net income	US$35.2M(₩48.5B)	US$102.1M(₩141B)	−US$100.2M(−₩138.2B)

Revenue

FY2023US$49.9M
FY2024US$52.2M
FY2025US$61.9M

Operating profit

FY2023US$5.6M
FY2024US$1.8M
FY2025US$3.2M

Net income

FY2023US$35.2M
FY2024US$102.1M
FY2025−US$100.2M

Key ratios (FY2025)

ROE

-66.3%

Debt/Eq

119.0%

Op. margin

5.2%

Net margin

-161.7%

Rev. YoY

▲ +18.6%

Price charts coming soon

Interactive price history isn't here yet. Would you use it?